The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer
Open accessAbstract
After an initial response to chemotherapy, many patients with triple-negative breast cancer (TNBC) have recurrence of drug-resistant metastatic disease.Studies with TNBC cells suggest that chemotherapy-resistant populations of cancer stem-like cells (CSCs) with self-renewing and tumor-initiating capacities are responsible for these relapses.TGF-β has been shown to increase stem-like properties in human breast cancer cells.We analyzed RNA expression in matched pairs of primary breast cancer biopsies before and after chemotherapy.Biopsies after chemotherapy displayed increased RNA transcripts of genes associated with CSCs and TGF-β signaling.In TNBC cell lines and mouse xenografts, the chemotherapeutic drug paclitaxel increased autocrine TGF-β signaling and IL-8 expression and enriched for CSCs, as indicated by mammosphere formation and CSC markers.The TGF-β type I receptor kinase inhibitor LY2157299, a neutralizing TGF-β type II receptor antibody, and SMAD4 siRNA all blocked paclitaxel-induced IL8 transcription and CSC expansion.Moreover, treatment of TNBC xenografts with LY2157299 prevented reestablishment of tumors after paclitaxel treatment.These data suggest that chemotherapy-induced TGF-β signaling enhances tumor recurrence through IL-8-dependent expansion of CSCs and that TGF-β pathway inhibitors prevent the development of drug-resistant CSCs.These findings support testing a combination of TGF-β inhibitors and anticancer chemotherapy in patients with TNBC. Results Chemotherapy-treated breast cancers display increased markers of TGF-β signaling and CSCs.We first examined gene expression signatures enriched by chemotherapy in primary breast cancers (Table 1).RNA extracted from 17 matched breast tumor biopsies before and after Conflict of interest: The authors have declared that no conflict of interest exists.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prospective identification of tumorigenic breast cancer cells
Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M. F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0530291100 · Cited by 10,370
The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells
Mani, S. A., Guo, W., Liao, M.-J., Eaton, E. N., Ayyanan, A., Zhou, A. Y., Brooks, M., Reinhard, F., Zhang, C. C., Shipitsin, M., et al. (2008) · Cell · doi:10.1016/j.cell.2008.03.027 · Cited by 8,672
Triple-negative breast cancer: clinical features and patterns of recurrence
Dent, R., Trudeau, M., Pritchard, K. I., Hanna, W. M., Kahn, H. K., Sawka, C. A., Lickley, L. A., Rawlinson, E., Sun, P., & Narod, S. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3045 · Cited by 5,091 · cited 1×
“Triple-negative breast cancers (TNBCs) lack detectable hormone receptors and ERBB2 gene amplification and represent the most virulent subtype of this malignancy (1).”
Ginestier, C., Hur, M. H., Charafe-Jauffret, E., Monville, F., Dutcher, J., Brown, M., Jacquemier, J., Viens, P., Kleer, C. G., Liu, S., et al. (2007) · Cell Stem Cell · doi:10.1016/j.stem.2007.08.014 · Cited by 4,012
Cancer stem cells in solid tumours: accumulating evidence and unresolved questions
Visvader, J. E., & Lindeman, G. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2499 · Cited by 3,429
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes
Neve, R. M., Chin, K., Fridlyand, J., Yeh, J., Baehner, F. L., Fevr, T., Clark, L., Bayani, N., Coppe, J.-P., Tong, F., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.008 · Cited by 3,188
Liedtke, C., Mazouni, C., Hess, K. R., André, F., Tordai, A., Mejia, J. A., Symmans, W. F., Gonzalez-Angulo, A. M., Hennessy, B., Green, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4147 · Cited by 2,892
TGF-β Signaling in Tumor Suppression and Cancer Progression
Derynck, R., Akhurst, R. J., & Balmain, A. (2001) · Nature Genetics · doi:10.1038/ng1001-117 · Cited by 2,275
The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes
Carey, L. A., Dees, E. C., Sawyer, L., Gatti, L., Moore, D. T., Collichio, F., Ollila, D. W., Sartor, C. I., Graham, M. L., & Perou, C. M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1109 · Cited by 2,087
Hu, Y., & Smyth, G. K. (2009) · Journal of Immunological Methods · doi:10.1016/j.jim.2009.06.008 · Cited by 2,083
Direct multiplexed measurement of gene expression with color-coded probe pairs
Geiss, G. K., Bumgarner, R. E., Birditt, B., Dahl, T., Dowidar, N., Dunaway, D. L., Fell, H. P., Ferree, S., George, R. D., Grogan, T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1385 · Cited by 2,066
Intrinsic Resistance of Tumorigenic Breast Cancer Cells to Chemotherapy
Li, X., Lewis, M. T., Huang, J., Gutierrez, C., Osborne, C. K., Wu, M.-F., Hilsenbeck, S. G., Pavlick, A., Zhang, X., Chamness, G. C., et al. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn123 · Cited by 1,794
Inman, G. J., Nicolás, F. J., Callahan, J. F., Harling, J. D., Gaster, L. M., Reith, A. D., Laping, N. J., & Hill, C. S. (2002) · Molecular Pharmacology · doi:10.1124/mol.62.1.65 · Cited by 1,634
Creighton, C. J., Li, X., Landis, M., Dixon, J. M., Neumeister, V. M., Sjolund, A., Rimm, D. L., Wong, H., Rodriguez, A., Herschkowitz, J. I., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905718106 · Cited by 1,412
Molecular Definition of Breast Tumor Heterogeneity
Shipitsin, M., Campbell, L. L., Argani, P., Weremowicz, S., Bloushtain-Qimron, N., Yao, J., Nikolskaya, T., Serebryiskaya, T., Beroukhim, R., Hu, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.01.013 · Cited by 1,353
Cancer Stem Cells: Models and Concepts
Dalerba, P., Cho, R. W., & Clarke, M. F. (2007) · Annual Review of Medicine · doi:10.1146/annurev.med.58.062105.204854 · Cited by 1,274
TGFβ: the molecular Jekyll and Hyde of cancer
Bierie, B., & Moses, H. L. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1926 · Cited by 1,267
Charafe-Jauffret, E., Ginestier, C., Iovino, F., Wicinski, J., Cervera, N., Finetti, P., Hur, M.-H., Diebel, M. E., Monville, F., Dutcher, J., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2741 · Cited by 1,173
Bakin, A. V., Tomlinson, A. K., Bhowmick, N. A., Moses, H. L., & Arteaga, C. L. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m005912200 · Cited by 992
Self-citationTGFβ Primes Breast Tumors for Lung Metastasis Seeding through Angiopoietin-like 4
Padua, D., Zhang, X. H.-F., Wang, Q., Nadal, C., Gerald, W. L., Gomis, R. R., & Massagué, J. (2008) · Cell · doi:10.1016/j.cell.2008.01.046 · Cited by 952
CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts
Ginestier, C., Liu, S., Diebel, M. E., Korkaya, H., Luo, M., Brown, M., Wicinski, J., Cabaud, O., Charafe-Jauffret, E., Birnbaum, D., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci39397 · Cited by 747
Ras and TGFβ cooperatively regulate epithelial cell plasticity and metastasis
Janda, E., Lehmann, K., Killisch, I., Jechlinger, M., Herzig, M., Downward, J., Beug, H., & Grünert, S. (2002) · The Journal of Cell Biology · doi:10.1083/jcb.200109037 · Cited by 706
Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway
Kang, Y., He, W., Tulley, S., Gupta, G. P., Serganova, I., Chen, C.-R., Manova-Todorova, K., Blasberg, R., Gerald, W. L., & Massagué, J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506517102 · Cited by 532
NANOG Is a Direct Target of TGFβ/Activin-Mediated SMAD Signaling in Human ESCs
Xu, R.-H., Sampsell-Barron, T. L., Gu, F., Root, S., Peck, R. M., Pan, G., Yu, J., Antosiewicz-Bourget, J., Tian, S., Stewart, R., et al. (2008) · Cell Stem Cell · doi:10.1016/j.stem.2008.07.001 · Cited by 511
DaCosta Byfield, S., Major, C., Laping, N. J., & Roberts, A. B. (2004) · Molecular Pharmacology · doi:10.1124/mol.65.3.744 · Cited by 414
A clinically relevant gene signature in triple negative and basal-like breast cancer
Rody, A., Karn, T., Liedtke, C., Pusztai, L., Ruckhaeberle, E., Hanker, L., Gaetje, R., Solbach, C., Ahr, A., Metzler, D., et al. (2011) · Breast Cancer Research · doi:10.1186/bcr3035 · Cited by 338
Wang, Y., Yu, Y., Tsuyada, A., Ren, X., Wu, X., Stubblefield, K., Rankin-Gee, E. K., & Wang, S. E. (2011) · Oncogene · doi:10.1038/onc.2010.531 · Cited by 263
Bendre, M. S., Margulies, A. G., Walser, B., Akel, N. S., Bhattacharrya, S., Skinner, R. A., Swain, F., Ramani, V., Mohammad, K. S., Wessner, L. L., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2630 · Cited by 243
Hwang-Verslues, W. W., Kuo, W.-H., Chang, P.-H., Pan, C.-C., Wang, H.-H., Tsai, S.-T., Jeng, Y.-M., Shew, J.-Y., Kung, J. T., Chen, C.-H., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0008377 · Cited by 223
Bueno, L., de Alwis, D. P., Pitou, C., Yingling, J., Lahn, M., Glatt, S., & Trocóniz, I. F. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2007.10.008 · Cited by 201
Targeting breast cancer stem cells
McDermott, S. P., & Wicha, M. S. (2010) · Molecular Oncology · doi:10.1016/j.molonc.2010.06.005 · Cited by 193
Ganapathy, V., Ge, R., Grazioli, A., Xie, W., Banach-Petrosky, W., Kang, Y., Lonning, S., McPherson, J., Yingling, J. M., Biswas, S., et al. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-122 · Cited by 168
Exploring anti-TGF-β therapies in cancer and fibrosis
Hawinkels, L. J. A. C., & ten Dijke, P. (2011) · Growth Factors · doi:10.3109/08977194.2011.595411 · Cited by 147
Bierie, B., Stover, D. G., Abel, T. W., Chytil, A., Gorska, A. E., Aakre, M. E., Forrester, E., Yang, H. H., Wagner, K., & Moses, H. L. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5597 · Cited by 128
Zhong, Z., Carroll, K. D., Policarpio, D., Osborn, C., Gregory, M., Bassi, R., Jimenez, X., Prewett, M., Liebisch, G., Persaud, K., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1634 · Cited by 123
TGFβ induces the formation of tumour-initiating cells in claudinlow breast cancer
Bruna, A., Greenwood, W., Quesne, J. P. C. L., Teschendorff, A. E., Miranda‐Saavedra, D., Rueda, O. M., Sandoval, J. L., Vidaković, A. T., Saadi, A., Pharoah, P. D. P., et al. (2012) · Nature Communications · doi:10.1038/ncomms2039 · Cited by 112
Bauer, J. A., Ye, F., Marshall, C. B., Lehmann, B. D., Pendleton, C. S., Shyr, Y., Arteaga, C. L., & Pietenpol, J. A. (2010) · Breast Cancer Research · doi:10.1186/bcr2595 · Cited by 91
Self-citationTorrisi, R., Balduzzi, A., Ghisini, R., Rocca, A., Bottiglieri, L., Giovanardi, F., Veronesi, P., Luini, A., Orlando, L., Viale, G., et al. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0652-z · Cited by 89
Gonzalez-Angulo, A. M., Iwamoto, T., Liu, S., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2762 · Cited by 77
Gupta, J., Robbins, J., Jilling, T., & Seth, P. K. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.11.3.14096 · Cited by 48
Conlin, A. K., & Seidman, A. D. (2008) · Clinical Breast Cancer · doi:10.3816/cbc.2008.n.024 · Cited by 31
Rodon, J. A., Baselga, J. M., Calvo, E., Seoane, J., Braña, I., Sicart, E., Gueorguieva, I., Cleverly, A., Lahn, M., Pillay, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.3011 · Cited by 29
Chhipa, R. R., & Bhat, M. K. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21153 · Cited by 28
Azaro, A., Baselga, J. M., Sepúlveda-Sánchez, J. M., Seoane, J., Rodon, J. A., Braña, I., Gueorguieva, I., Cleverly, A., Lahn, M. M. F., Pillay, S., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.2042 · Cited by 11
Cited by
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
Bianchini, G., Balko, J. M., Mayer, I. A., Sanders, M. E., & Gianni, L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.66 · Cited by 3,079
Self-citationGarrido-Castro, A. C., Lin, N. U., & Polyak, K. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1177 · Cited by 1,451
Combination cancer immunotherapy and new immunomodulatory targets
Mahoney, K. M., Rennert, P. D., & Freeman, G. J. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4591 · Cited by 1,294
Drug resistance and combating drug resistance in cancer
Wang, X., Zhang, H., & Chen, X. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.10 · Cited by 1,085
Targeting TGF-β Signaling in Cancer
Colak, S., & ten Dijke, P. (2017) · Trends in cancer · doi:10.1016/j.trecan.2016.11.008 · Cited by 1,003
Metadata
- Authors
- Bhola, N. E., Balko, J. M., Dugger, T. C., Kuba, M. G., Sánchez, V., Sanders, M., Stanford, J., Cook, R. S., & Arteaga, C. L.
- Venue
- Journal of Clinical Investigation
- Published
- 2013-02-08
- Volume
- 123
- Issue
- 3
- Pages
- 1348-1358
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2114639059
- Cited by
- 590
- References
- 44
- FWCI
- 23.08
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.